Attached files
| file | filename |
|---|---|
| EX-99.2 - PRESS RELEASE - Bionik Laboratories Corp. | bnkl_announcesnoblepresen.htm |
| EX-99.1 - INVESTOR PRESENTATION - Bionik Laboratories Corp. | bnkl_investorpresentation.htm |
|
UNITED STATES
|
|
SECURITIES AND EXCHANGE COMMISSION
|
|
WASHINGTON, DC 20549
|
|
|
|
|
|
FORM 8-K
|
|
CURRENT REPORT PURSUANT
|
|
TO SECTION 13 OR 15(D) OF THE
|
|
SECURITIES EXCHANGE ACT OF 1934
|
|
|
|
Date of
report (Date of earliest event reported): January 24, 2017
|
|
BIONIK
LABORATORIES CORP.
|
|
(Exact
Name of Registrant as Specified in Its Charter)
|
|
Delaware
|
|
000-54717
|
|
27-1340346
|
|
(State
or Other Jurisdiction of Incorporation or
Organization)
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
|
483 Bay Street, N105
Toronto, ON
|
|
M5G 2C9
|
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
|
Registrant’s
Telephone Number, Including Area Code: (416) 640-7887
|
||
|
|
||
|
|
||
|
(Former
Name or Former Address, if Changed Since Last Report)
|
||
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
|
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
|
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
|
Item 7.01
|
Regulation FD Disclosure
|
Bionik
Laboratories Corp. (the “Registrant”) is furnishing
presentation materials included as Exhibit 99.1 to this report
pursuant to Item 7.01 of Form 8-K. The Registrant is not
undertaking to update this presentation. The information in this
report (including Exhibit 99.1) is being furnished pursuant to Item
7.01 and shall not be deemed to be “filed” for the
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended, or otherwise subject to the liabilities of that section.
This report will not be deemed an admission as to the materiality
of any information herein (including Exhibit 99.1).
|
Item 8.01
|
Other Events
|
On
January 24, 2017, the Registrant issued a press release disclosing
that the Registrant will present at NobleCon13, the Noble Capital
Markets' Thirteenth Annual Investor Conference, on January 31, 2017
at 12:00 p.m. ET in Boca Raton, FL.
A
copy of the press release is filed as Exhibit 99.2 to this Current
Report on Form 8-K and is incorporated herein by
reference.
|
Item 9.01
|
Financial Statements and Exhibits
|
(d)
Exhibits
Exhibit
No. Description
99.1 Presentation
Materials
99.2 Press
Release dated January 24, 2017
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
Date: January 30, 2017
|
|
BIONIK LABORATORIES CORP.
|
|
|
|
|
|
|
|
By:
|
/s/
Leslie
Markow
|
|
|
Name:
|
Leslie
Markow
|
|
|
Title:
|
Chief
Financial Officer
|